GSK and Boehringer Ingelheim to assess the development of HIV medicines
GlaxoSmithKline (GSK) and Boehringer Ingelheim have entered into discussions to assess the development of co-packaging of antiretrovirals for the treatment of HIV infection in the developing world.
GlaxoSmithKline (GSK) and Boehringer Ingelheim have entered into discussions to assess the development of co-packaging of antiretrovirals for the treatment of HIV infection in the developing world.
'We are committed to playing an integral role in the global response to HIV/AIDS through sustainable preferential pricing, innovative partnership, community investment, and research and development of new medicines and vaccines to fight disease,' said Jean-Pierre Garnier, ceo of GlaxoSmithKline. 'Both GSK and BI believe co-packaging could be a useful option in treating the millions of individuals living with HIV in the developing world.'